Kinase Inhibitors

Larotrectinib sulfate View larger

Larotrectinib sulfate

AOB33500

CAS No: 1223405-08-0

 

Chemical Name: LOXO-101 sulfate; (3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide sulfate

More details

Molarity Calculation Cart®

HOW TO ORDER

$7.50

$7.50 per mg

Quantity Discount Table - Order More To Get More Price Discount

QuantitymgUnit Price ($/mg or $/Unit)Final Price
1100 $3.38 Total: $337.50
150 $3.90 Total: $195.00
125 $4.58 Total: $114.38
110 $5.40 Total: $54.00
15 $6.38 Total: $31.88

Data sheet

Molecular FormulaC21H24F2N6O6S
Molecular Weight526.52
CAS Numbers1223405-08-0
Storage Condition0°C (short term), -20°C (long term), desiccated
SolubilityDMSO
Purity98% by HPLC
SynonymLarotrectinib sulfate; LOXO-101 sulfate; LOXO 101 sulfate; LOXO101 sulfate; ARRY-470 sulfate; ARRY470 sulfate; ARRY 470 sulfate; Vitrakvi
IUPAC/Chemical Name(3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide sulfate
InChl KeyPXHANKVTFWSDSG-QLOBERJESA-N
InChl CodeInChI=1S/C21H22F2N6O2.H2O4S/c22-13-3-4-16(23)15(10-13)18-2-1-7-28(18)19-6-9-29-20(26-19)17(11-24-29)25-21(31)27-8-5-14(30)12-27;1-5(2,3)4/h3-4,6,9-11,14,18,30H,1-2,5,7-8,12H2,(H,25,31);(H2,1,2,3,4)/t14-,18+;/m0./s1
SMILES CodeO=C(N1C[C@@H](O)CC1)NC2=C3N=C(N4[C@@H](C5=CC(F)=CC=C5F)CCC4)C=CN3N=C2.O=S(O)(O)=O
PubChem ID1) Attia MH, Elrazaz EZ, El-Emam SZ, Taher AT, Abdel-Aziz HA, Abouzid KAM. Synthesis and in-vitro anti-proliferative evaluation of some pyrazolo[1,5-a]pyrimidines as novel larotrectinib analogs. Bioorg Chem. 2019 Nov 21:103458.

2) Bielack SS, Cox MC, Nathrath M, Apel K, Blattmann C, Holl T, Jenewein R, Klenk U, Klothaki P, Müller-Abt P, Ortega-Lawerenz S, Reynolds M, Scheer M, Simon-Klingenstein K, Stegmaier S, Tupper R, Vokuhl C, von Kalle T. Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion. Ann Oncol. 2019 Nov 1;30(Supplement_8):viii31-viii35.

More info

Novel oral potent and selective ATP-competitive inhibitor of tropomyosin receptor kinases (TRK).

Customers who bought this product also bought: